Krebs Biochemicals and Industries Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Krebs Biochemicals reported a sharp deterioration in Q1 FY26 (quarter ended June 30, 2025). Revenue from operations fell about 57% YoY to ₹548 lakhs, down from ₹1,289 lakhs a year earlier. Total expenses surged to ₹3,619 lakhs (from ₹1,469 lakhs), driven by a roughly 12x jump in finance costs to ₹1,660 lakhs versus ₹132 lakhs in Q1 FY25, indicating a heavy debt burden. The company posted a net loss of ₹532 lakhs (EPS of negative ₹2.47), marginally wider than the ₹517 lakh loss in the year-ago quarter. The Vizag manufacturing unit remains shut following an Andhra Pradesh Pollution Control Board order dated February 7, 2025, and net worth stands deeply negative at around ₹(14,624) lakhs as of March 31, 2025. Separately, Manish Kumar Jain has been appointed as Managing Director & CEO for a five-year term, replacing Jitendra Shah who resigned for personal reasons.
The combination of collapsing revenue, ballooning finance costs, a closed manufacturing plant, and deeply negative net worth signals serious financial distress and a likely going-concern issue — investors should treat this as a high-risk situation with possible dilution, restructuring, or further decline ahead.